SCHEMBL6032322

SCHEMBL6032322

NS(=O)(=O)c1ccccc1C(=O)NN1CCCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 7/20 0.59
CA2 P00918 7/20 0.59
CA9 Q16790 7/20 0.59
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
HTT P42858 1/20 0.51
CA5A P35218 1/20 0.50
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
GAA P10253 1/20 0.43
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP3 P08254 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP12 P39900 1/20 0.41
MMP13 P45452 1/20 0.41
MMP14 P50281 1/20 0.41
MMP16 P51512 1/20 0.41
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30385340 1.00 CA1 (0.59) CA1CA2CA9LMNAPOLB
SCHEMBL15690459 0.79 MAPT (0.48) CA1CA2CA9LMNAPOLB
SCHEMBL10674689 0.76 CA1 (0.54) CA1CA2CA9LMNAHTT
SCHEMBL6553709 0.76 HTT (0.64) LMNAPOLBHTTGAATDP1
SCHEMBL27805191 0.75 CA1 (1.00) CA1CA2CA9CA5APRMT5
SCHEMBL30202428 0.75 CA1 (0.73) CA1CA2CA9LMNACA5A
SCHEMBL14794997 0.75 CA1 (0.54) CA1CA2CA9LMNAPOLB
SCHEMBL10435055 0.74 CA2 (0.71) CA1CA2CA9POLBCA5A
SCHEMBL8971757 0.73 CA1 (0.52) CA1CA2CA9LMNAHTT
SCHEMBL10678250 0.73 ALDH1A1 (0.57) CA1CA2CA9POLBCA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6982281-B1 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs LIPOCINE INC (US) 2006-01-03 US disclosed
US-20050171193-A1 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs LIPOCINE, INC. 2005-08-04 US disclosed
WO-2004087052-A2 OIL-CONTAINING, ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITION FOR IMPROVED DELIVERY OF A THERAPEUTIC AGENT LIPOCINE, INC. (US) 2004-10-14 WO disclosed
US-20030235595-A1 Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent LIPOCINE, INC. 2003-12-25 US disclosed
WO-2002039983-A2 PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS LIPOCINE, INC. (US) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171193-A1 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs LIPC, TTPA, LIPA CA1 3419/4885CA2 2296/4885CA9 2810/4885
US-20030235595-A1 Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent LIPA, LIPC, CETP CA1 4489/4885CA2 3660/4885CA9 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.